Další formáty:
BibTeX
LaTeX
RIS
@article{2231684,
author = {Singh, Ambrish and Hussain, Mohammad Salman and Akkala, Sreelatha and Klugarová, Jitka and Pokorná, Andrea and Klugar, Miloslav and Walters, E. Haydn and Hopper, Ingrid and Campbell, Julie A. and Taylor, Bruce and Antony, Benny},
article_location = {CLARE},
article_number = {September 2022},
doi = {http://dx.doi.org/10.1016/j.arr.2022.101670},
keywords = {Beta-adrenoceptors; Beta-blockers; Beta -antagonist; Beta-agonist; Propranolol; Salbutamol; Parkinson ?s disease},
language = {eng},
issn = {1568-1637},
journal = {AGEING RESEARCH REVIEWS},
title = {Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis},
url = {https://www.sciencedirect.com/science/article/pii/S156816372200112X?via%3Dihub},
volume = {80},
year = {2022}
}
TY - JOUR
ID - 2231684
AU - Singh, Ambrish - Hussain, Mohammad Salman - Akkala, Sreelatha - Klugarová, Jitka - Pokorná, Andrea - Klugar, Miloslav - Walters, E. Haydn - Hopper, Ingrid - Campbell, Julie A. - Taylor, Bruce - Antony, Benny
PY - 2022
TI - Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis
JF - AGEING RESEARCH REVIEWS
VL - 80
IS - September 2022
SP - 1-13
EP - 1-13
PB - ELSEVIER IRELAND LTD
SN - 15681637
KW - Beta-adrenoceptors
KW - Beta-blockers
KW - Beta -antagonist
KW - Beta-agonist
KW - Propranolol
KW - Salbutamol
KW - Parkinson ?s disease
UR - https://www.sciencedirect.com/science/article/pii/S156816372200112X?via%3Dihub
N2 - Background: Parkinson's Disease (PD) is a neurodegenerative disorder manifested by rest tremor, rigidity, bradykinesia, and postural instability. Recent pharmaco-epidemiological studies evaluating beta-adrenergic drug use and risk of PD have reported conflicting findings. Objectives: This systematic review and meta-analyses evaluate the association between beta-adrenergic (agonists and antagonists) drugs' use and PD. Methods: An electronic literature search of eight databases was performed from inception to July 2021 to identify pharmaco-epidemiological studies (case-control and cohort) reporting the risk of PD in beta-adrenergic users compared to non-users. We used the generic inverse variance method and RevMan (5.3.5) to estimate pooled adjusted risk ratios (aRRs) of PD using a random-effects model. Results: Of 3168 records, 15 studies (10 case-control; five cohort) with 6508,877 participants, including 87,011 PD cases, were included. In the pooled analysis (n = 10) including any beta-antagonist users, compared with nonusers, the aRR for PD was 1.19 (CI: 1.05,1.35); for any beta-agonist users (n = 8) aRR for PD was 0.87 (CI: 0.78,0.97). Propranolol users had a significantly increased risk of PD (aRR:1.91; CI:1.20,3.06), whereas salbutamol use was associated with reduced risk of PD (aRR:0.95; CI:0.92,0.99). Significant heterogeneity (I2 >87%) was observed, but the majority (n = 13) of the studies were of high quality, based on the JBI tool. Conclusions: Beta-antagonist use was associated with a modestly increased risk of PD, whereas beta-agonist use was associated with a modest decreased risk of PD. Future epidemiological studies should address the issues of protopathic bias and indirect association using appropriate epidemiological methods.
ER -
SINGH, Ambrish, Mohammad Salman HUSSAIN, Sreelatha AKKALA, Jitka KLUGAROVÁ, Andrea POKORNÁ, Miloslav KLUGAR, E. Haydn WALTERS, Ingrid HOPPER, Julie A. CAMPBELL, Bruce TAYLOR a Benny ANTONY. Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis. \textit{AGEING RESEARCH REVIEWS}. CLARE: ELSEVIER IRELAND LTD, 2022, roč.~80, September 2022, s.~1-13. ISSN~1568-1637. Dostupné z: https://dx.doi.org/10.1016/j.arr.2022.101670.
|
